CN113440529A - Injectable pharmaceutical composition and preparation method thereof - Google Patents
Injectable pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN113440529A CN113440529A CN202110317250.8A CN202110317250A CN113440529A CN 113440529 A CN113440529 A CN 113440529A CN 202110317250 A CN202110317250 A CN 202110317250A CN 113440529 A CN113440529 A CN 113440529A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- rilpivirine
- surface stabilizer
- sodium
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims description 16
- 229960002814 rilpivirine Drugs 0.000 claims abstract description 111
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims abstract description 109
- 239000003381 stabilizer Substances 0.000 claims abstract description 98
- 239000002105 nanoparticle Substances 0.000 claims abstract description 38
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 13
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 13
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000002245 particle Substances 0.000 claims description 46
- 239000002202 Polyethylene glycol Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229960003964 deoxycholic acid Drugs 0.000 claims description 23
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 23
- 238000004062 sedimentation Methods 0.000 claims description 18
- BKVAAWMQOQLENB-UHFFFAOYSA-N 15-hydroxy stearic acid Chemical compound CCCC(O)CCCCCCCCCCCCCC(O)=O BKVAAWMQOQLENB-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000003801 milling Methods 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 8
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229940100242 glycol stearate Drugs 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 229940069328 povidone Drugs 0.000 claims description 5
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 5
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 5
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 102100034343 Integrase Human genes 0.000 claims description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229940119744 dextran 40 Drugs 0.000 claims description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 229960002449 glycine Drugs 0.000 claims description 3
- 229940124524 integrase inhibitor Drugs 0.000 claims description 3
- 239000002850 integrase inhibitor Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 3
- 229940074410 trehalose Drugs 0.000 claims description 3
- 239000012931 lyophilized formulation Substances 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 229920013747 hydroxypolyethylene Polymers 0.000 claims 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 description 22
- -1 polyethylene Polymers 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 229960001031 glucose Drugs 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 229960000502 poloxamer Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 229960003804 efavirenz Drugs 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920003079 Povidone K 17 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- MPNGLQDRSJNLPL-UHFFFAOYSA-N 4-[[2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-chlorobenzoic acid Chemical compound ClC1=CC(C(=O)O)=CC=C1NC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 MPNGLQDRSJNLPL-UHFFFAOYSA-N 0.000 description 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
- CGBYTKOSZYQOPV-ASSBYYIWSA-N 5-chloro-3-[[3-[(e)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1h-indole-2-carboxamide Chemical compound C1([P@](=O)(C=2C3=CC(Cl)=CC=C3NC=2C(N)=O)OC)=CC(C)=CC(\C=C\C#N)=C1 CGBYTKOSZYQOPV-ASSBYYIWSA-N 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 229950004424 alovudine Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229950005846 amdoxovir Drugs 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- ZRBROGSAUIUIJE-UHFFFAOYSA-N azanium;azane;chloride Chemical compound N.[NH4+].[Cl-] ZRBROGSAUIUIJE-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229950005928 cabotegravir Drugs 0.000 description 1
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- RZHBMYQXKIDANM-UHFFFAOYSA-N dioctyl butanedioate;sodium Chemical compound [Na].CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC RZHBMYQXKIDANM-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 229950006528 elvucitabine Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- HCFQUUYOZKJEDC-UHFFFAOYSA-M heptyl(trimethyl)azanium;bromide Chemical compound [Br-].CCCCCCC[N+](C)(C)C HCFQUUYOZKJEDC-UHFFFAOYSA-M 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 1
- 229950008687 oltipraz Drugs 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 description 1
- 229950006460 palinavir Drugs 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229940100528 polyoxyl 8 stearate Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- BNWLSWDFUNRHCC-UHFFFAOYSA-N pyridin-1-ium chloride sulfate Chemical compound S(=O)(=O)([O-])[O-].[Cl-].[NH+]1=CC=CC=C1.[NH+]1=CC=CC=C1.[NH+]1=CC=CC=C1 BNWLSWDFUNRHCC-UHFFFAOYSA-N 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to an injectable pharmaceutical composition and a method of preparing the same. In particular, the pharmaceutical compositions described in the present disclosure comprise rilpivirine nanoparticles and a surface stabilizer. The pharmaceutical composition provided by the disclosure relates to the application of the pharmaceutical composition in the treatment and prevention of HIV infection, has good stability, and is suitable for industrial production.
Description
Technical Field
The disclosure relates to the field of pharmaceutical preparations, in particular to an injectable pharmaceutical composition containing nanoparticles of rilpivirine and a preparation method thereof.
Background
Acquired Immune Deficiency Syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which is feared in that it targets the most important CD 4T lymphocyte in the human immune system as a major attack, destroying it in large quantities, and depriving the human body of immune function. Treatment compliance and pubic sympathy remain major obstacles to combating the HIV-1 epidemic. In China, AIDS has already entered a rapid growth period, and the epidemic development trend is severe. Therefore, the search for effective treatments for aids has become a major and worldwide concern.
Rilpivirine is white to white-like powder, has a diaryl pyrimidine structure, can be tightly allosterically combined with reverse transcriptase of HIV-1, is used as a strong non-nucleoside reverse transcriptase inhibitor (NNRTI), intervenes in the early stage of virus HIV replication cycle, and prevents virus DNA synthesis and subsequent integration of virus genome in host DNA; compared with other non-nucleoside reverse transcriptase inhibitors (efavirenz), rilpivirine has the advantages of small nerve and metabolic side effects and good tolerance. The currently marketed rilpivirine tablets have the specification of 25 mg/tablet, and are orally taken by patients one tablet per day, so that the rilpivirine tablets have obvious food effect and need to be taken after a meal. Because rilpivirine raw material has poor water solubility and oil solubility, the bioavailability of the tablet is low, and the rilpivirine raw material is sometimes required to be combined with other anti-AIDS drugs.
Other anti-HIV drugs currently in use require frequent administration of relatively high doses (efavirenz (600 mg/day), lamivudine (300 mg/day)), frequency of intake, and number and volume of administrations increase the risk of patients not taking the full dose and thereby failing to comply with the prescribed dosage regimen. This not only reduces the effectiveness of the treatment but also results in the development of viral resistance, and it is therefore necessary to design an anti-HIV therapy that does not require frequent dosing. The rilpivirine nanocrystal has obvious clinical advantages, does not need carrier materials, only needs a small amount of stabilizing agents, has no toxicity problems (such as hemolysis, anaphylactic reaction and the like) caused by excipients, is not limited by encapsulation rate and drug-loading rate, and can meet the requirements of high-dose and high-concentration preparations. The rilpivirine nano particles prepared can be used as a preparation storage, is slowly dissolved and absorbed by a human body, and is applied at long time intervals, such as one month or more, so as to achieve the effects of preventing and treating HIV for a long time.
CN101478950A discloses a pharmaceutical composition comprising rilpivirine in nanoparticle form, a surface modifying agent and a pharmaceutically acceptable carrier. CN108210469A discloses a pharmaceutical composition comprising rilpivirine, a surfactant and a lyoprotectant. CN101636149B discloses a supersaturated solution comprising rilpivirine and a water soluble polymer selected from polyvinylpyrrolidone, a copolymer of vinylpyrrolidone and vinyl acetate, a hydroxyalkyl alkylcellulose, and a poloxamer, in an aqueous medium. WO2015136294a1 discloses pharmaceutical compositions comprising rilpivirine in nanoparticulate form and one or more pharmaceutically acceptable excipients.
Disclosure of Invention
The present disclosure provides a pharmaceutical composition comprising rilpivirine nanoparticles and a surface stabilizer, wherein the surface stabilizer comprises a first surface stabilizer polyethylene glycol stearate or a derivative thereof and a second surface stabilizer selected from one or more of sodium deoxycholate, sodium cholate, sodium hydroxymethylcellulose, sodium docusate, preferably one or more of sodium deoxycholate, sodium hydroxymethylcellulose, more preferably sodium deoxycholate.
The polyethylene glycol stearate or derivatives thereof of the present disclosure include, but are not limited to, polyethylene glycol-660-hydroxystearate, polyethylene glycol-15-hydroxystearate, polyethylene glycol-400-monostearate, polyoxyethylene castor oil derivatives (including, but not limited to Cremophor EL, Cremophor RH40, Cremophor RH60), and the like, preferably polyethylene glycol 15-hydroxystearate.
The pharmaceutical composition of the present disclosure comprises rilpivirine nanoparticles, a first surface stabilizer, a second surface stabilizer, and may further comprise additional surface stabilizers, pH modifiers, antioxidants, photolytic agents, emulsifiers, lyoprotectants, bacteriostatic preservatives, isotonic adjusting agents, sedimentation inhibitors, liquid media, and the like.
The surfactant can be nonionic, anionic, cationic and zwitterionic compound or surfactant, and is selected from one or more of polyvidone, polyoxyethylene sorbitan fatty acid ester, sodium deoxycholate, polyethylene glycol stearate, poloxamer, 15-hydroxystearic acid polyethylene glycol ester, polyvinyl alcohol, docusate sodium, hydroxypropyl methylcellulose, lecithin, sodium cholate, and hydroxymethyl cellulose sodium. Non-ionic surface stabilizers described in the present disclosure include, but are not limited to, Hydroxypropylmethylcellulose (HPMC), povidone, poloxamer, polyoxyethylene sorbitan fatty acid ester, polyethylene glycol stearate, polyethylene glycol 15-hydroxystearate. Anionic surface stabilizers described in the present disclosure include, but are not limited to, sodium dioctyl succinate (DOSS), sodium docusate, sodium cholate, sodium deoxycholate, and sodium hydroxymethyl cellulose. The cationic surface stabilizers described in this disclosure include, but are not limited to, polymers, biopolymers, poly-N-methylpyridinium, pyridinium sulfate chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polystyrene, polymethylmethacrylate trimethylammonium bromide (PMMTMABr), hexylmethyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethylmethacrylate dimethyl sulfate. The zwitterionic surface stabilizers described in this disclosure include, but are not limited to, proteins, phospholipids, zwitterionic polymers, and zwitterionic surfactant molecules, which can be, for example, phosphatidylcholine, lecithin, gelatin, and the like. The surface stabilizer described in the present disclosure includes not only the surface stabilizer described above in the conventional sense but also some additives equivalent to the above surface stabilizer, for example, a mixture of deoxycholic acid and sodium phosphate is equivalent to sodium deoxycholate.
Wherein the pH regulator includes but is not limited to hydrochloric acid, sulfuric acid, lactic acid, malic acid, acetic acid, citric acid, phosphoric acid, sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium dihydrogen phosphate, sodium citrate, arginine, etc.; antioxidants include, but are not limited to, L-cysteine hydrochloride, sodium sulfite, sodium bisulfite, propyl gallate, glutathione, sodium thiosulfate, vitamin E, thiourea, and the like; lyoprotectants include, but are not limited to, mannitol, arginine, povidone, dextran, and the like, and isotonicity adjusting agents include, but are not limited to, sodium chloride, glucose, sorbitol, phosphate, sodium citrate, and the like; sedimentation inhibitors include, but are not limited to, mannitol, dextrose sucrose, polyethylene glycol, dextran 40, trehalose, glycerol, povidone, glycine, hydroxypropyl- β -cyclodextrin, and the like; liquid media include, but are not limited to, water, saline solution, safflower seed oil, ethanol, t-butanol, hexane, ethylene glycol, and the like.
The nanoparticles may be prepared by co-milling, high pressure homogenization or anti-solvent methods, with co-milling being preferred. The liquid medium used for co-milling is selected from the group consisting of water, saline solution, safflower seed oil, ethanol, t-butanol, hexane and ethylene glycol, preferably water, saline solution, safflower seed oil, most preferably water or saline solution. One embodiment of the present disclosure is to co-grind rilpivirine and a surface stabilizer to obtain nanoparticles using water as a liquid medium.
The weight ratio of the surface stabilizer to the rilpivirine is 1: 0.01-1: 100, preferably 1: 1-1: 80, more preferably 1: 5-1: 30, and most preferably 1: 6.5-1: 20.
The weight ratio of the first surface stabilizer to rilpivirine is selected from 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 6-1: 60, and most preferably 1: 10-1: 30.
The weight ratio of the second surface stabilizer to rilpivirine is selected from 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 10-1: 60, and most preferably 1: 20-1: 60.
The weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 0.1:1 to 10:1, preferably 1:1 to 6:1, more preferably 1:1 to 2:1, and most preferably 2: 1.
In one embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 6-1: 60, most preferably 1: 10-1: 30; the weight ratio of the second surface stabilizer to rilpivirine is selected from 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 10-1: 60, and most preferably 1: 20-1: 60.
In another embodiment of the present disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:0.01 to 1:100, preferably 1:1 to 1:100, more preferably 1:6 to 1:60, most preferably 1:10 to 1: 30; the weight ratio of the second surface stabilizer to rilpivirine is 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 10-1: 60, and most preferably 1: 20-1: 60; the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 0.1:1 to 10:1, preferably 1:1 to 6:1, more preferably 1:1 to 2:1, and most preferably 2: 1.
In one embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:6 to 1:60, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:10 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 6: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:6 to 1:60, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:10 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 2: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:6 to 1:60, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:10 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 2: 1.
In one embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:6 to 1:60, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:20 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 6: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:6 to 1:60, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:20 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 2: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:6 to 1:60, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:20 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 2: 1.
In one embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:10 to 1:30, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:10 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 6: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:10 to 1:30, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:10 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 2: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:10 to 1:30, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:10 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 2: 1.
In one embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is 1: 10-1: 30, the weight ratio of the second surface stabilizer to rilpivirine is 1: 20-1: 60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is 1: 1-6: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:10 to 1:30, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:20 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 1:1 to 2: 1. In another embodiment of the disclosure, the weight ratio of the first surface stabilizer to rilpivirine is selected from 1:10 to 1:30, the weight ratio of the second surface stabilizer to rilpivirine is selected from 1:20 to 1:60, and the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 2: 1.
The pharmaceutical composition disclosed by the disclosure, wherein the weight ratio of the sodium deoxycholate, the 15-hydroxystearic acid polyethylene glycol ester and the rilpivirine is 1: 1-10: 1-100, preferably 1: 1-6: 10-100, more preferably 1: 1-5: 10-80, and most preferably 1: 1-3: 20-60.
The pharmaceutical composition of the present disclosure further comprises a sedimentation inhibitor, wherein the sedimentation inhibitor includes, but is not limited to, one or more of mannitol, glucose sucrose, polyethylene glycol, dextran 40, trehalose, glycerol, povidone, glycine, hydroxypropyl- β -cyclodextrin, preferably one or more of mannitol, glucose, and polyethylene glycol, and more preferably glucose. The weight ratio of the sedimentation inhibitor to rilpivirine is 1: 0.1-1: 50, preferably 1: 0.5-1: 30, more preferably 1: 3-1: 15, and more preferably 1: 3-1: 7.
The preparation method of the pharmaceutical composition comprises the following steps: co-milling the surface stabilizer, the sedimentation inhibitor and rilpivirine to prepare the nanoparticle composition.
In the pharmaceutical composition of the present disclosure, rilpivirine is contained in an amount selected from 0.01-800mg, preferably 10-600mg, more preferably 100-600mg, and most preferably 200-600 mg.
The pharmaceutical compositions of the present disclosure also comprise a liquid medium including, but not limited to, water, saline solution, safflower seed oil, ethanol, tert-butanol, hexane and ethylene glycol, preferably water, saline solution.
In the pharmaceutical composition disclosed by the invention, the content of rilpivirine is selected from 0.01-800 mg/mL, preferably 10-600 mg/mL, more preferably 100-500 mg/mL, and most preferably 200-350 mg/mL.
The average particle size of the rilpivirine nanoparticles is less than 1000nm, preferably less than 500nm, more preferably less than 250nm, more preferably less than 220nm, more preferably less than 200nm, more preferably less than 160nm, and most preferably less than 150 nm.
The average particle size of the rilpivirine nanoparticles of the pharmaceutical compositions of the present disclosure is no greater than 500nm, preferably no greater than 300nm, more preferably no greater than 250nm, and most preferably no greater than 200nm, when stored at 2-8 ℃ for about 30 days.
The pharmaceutical compositions of the present disclosure have a D50 value for rilpivirine nanoparticles of no greater than 500nm, preferably no greater than 300nm, more preferably no greater than 250nm, and most preferably no greater than 200nm when stored at 2-8 ℃ for about 30 days.
The D90 of rilpivirine nanoparticles of the pharmaceutical compositions of the present disclosure is no greater than 600nm, preferably no greater than 500nm, more preferably no greater than 350nm, and most preferably no greater than 300nm, when stored at 2-8 ℃ for about 30 days.
In one embodiment of the present disclosure, the average particle size of the rilpivirine nanoparticles is less than 500nm, preferably less than 250nm, more preferably less than 200nm, most preferably less than 150 nm; the average particle size of rilpivirine nanoparticles is no greater than 500nm, preferably no greater than 300nm, more preferably no greater than 250nm, most preferably no greater than 200nm, when stored at 2-8 ℃ for about 30 days; a value of D50 of no more than 500nm, preferably no more than 300nm, more preferably no more than 250nm, most preferably no more than 200 nm; d90 is not higher than 600nm, preferably not higher than 500nm, more preferably not higher than 350nm, most preferably not higher than 300 nm.
In one embodiment, the pharmaceutical composition of the present disclosure may be prepared as an injection or a lyophilized formulation.
The pharmaceutical composition of the present disclosure comprises, based on the weight to volume ratio of the composition: 3-50% w/v rilpivirine, preferably 10-40% w/v rilpivirine, more preferably 20-40% w/v rilpivirine; 0.1-10% w/v of a first surface stabilizer, preferably 0.5-5% w/v of the first surface stabilizer, more preferably 0.5-3% w/v of the first surface stabilizer; 0.01% to 3% w/v of a second surface stabilizer, preferably 0.1% to 1.5% w/v of a second surface stabilizer, more preferably 0.5% to 1.5% w/v of a second surface stabilizer; 0% to 10% w/v of a sedimentation inhibitor, preferably 3% to 8% w/v of a sedimentation inhibitor, more preferably 4% to 6% w/v of a sedimentation inhibitor; from 40% to 80% w/v of liquid medium, preferably from 50% to 80% w/v of liquid medium, more preferably from 60% to 75% w/v of liquid medium.
The pharmaceutical composition of the present disclosure comprises, based on the weight to volume ratio of the composition: 3-50% w/v rilpivirine, preferably 10-40% w/v rilpivirine, more preferably 20-40% w/v rilpivirine; 0.1-10% w/v of polyethylene glycol 15-hydroxystearate, preferably 0.5-5% w/v of polyethylene glycol 15-hydroxystearate, more preferably 0.5-3% w/v of polyethylene glycol 15-hydroxystearate; 0.01-3% w/v sodium deoxycholate, preferably 0.1-1.5% w/v sodium deoxycholate, more preferably 0.5-1.5% w/v sodium deoxycholate; 0% to 10% w/v glucose, preferably 3% to 8% w/v glucose, more preferably 4% to 6% w/v glucose; from 40% to 80% w/v water, preferably from 50% to 80% w/v water, more preferably from 60% to 75% w/v water.
The preparation method of the pharmaceutical composition comprises the step of co-grinding 15-hydroxystearic acid polyethylene glycol ester, sodium deoxycholate and rilpivirine to prepare rilpivirine nanoparticle composition. Preferably, the preparation method comprises the step of co-grinding 15-hydroxystearic acid polyethylene glycol ester, sodium deoxycholate, glucose and rilpivirine in a liquid medium to prepare the rilpivirine nanoparticle composition.
In one embodiment, the milling time is generally about 15 to 1 hour, preferably 10 to 1 hour, more preferably 8 to 1 hour, more preferably 6 to 1 hour, more preferably 5 to 1 hour, and most preferably 3 to 1 hour.
In one embodiment, rilpivirine is form I having characteristic peaks in the X-ray powder diffraction pattern at 2 Θ angles of 9.0 °, 11.3 °, 14.3 °,17.1 °, 19.1 °, 24.2 ° and 27.6 °; the crystal form I is a polymorphic form I described in patent CN 101743006.
In one embodiment, rilpivirine is crystalline form II having an X-ray powder diffraction pattern with characteristic peaks at 2 Θ angles of 8.3 °, 12.2 °, 12.6 °, 17.3 °, 20.7 °, 24.5 °, 25.5 ° and 27.6 °; the crystal form II is a polymorphic form II described in patent CN 101743006.
The "2 theta or 2 theta angle" referred to in the present disclosure means the diffraction angle, theta is the bragg angle in degrees or degrees, and the error range of 2 theta is ± 0.3 or ± 0.2 or ± 0.1.
Use of a pharmaceutical composition of the present disclosure in the manufacture of a medicament for treating HIV infection or preventing HIV infection in a subject at risk for being infected by HIV.
Use of a pharmaceutical composition described in the present disclosure for the manufacture of a medicament for the long-term treatment of an HIV infection or for the long-term prevention of an HIV infection in a subject at risk of being infected by HIV.
The medicaments of the present disclosure are for administration by intramuscular or subcutaneous injection; wherein the composition is administered intermittently at intervals of one week to two years, in one embodiment wherein the composition is administered at intervals of one week to one month, one month to three months, three months to six months, or six months to twelve months. In another embodiment, wherein the composition is administered once a week, once every two weeks, once every four weeks, once every month, or once every three months. The pharmaceutical composition disclosed by the invention has high bioavailability after subcutaneous injection, and has good safety and effectiveness.
The pharmaceutical composition of the present disclosure may also be used in combination with other HIV inhibitors, wherein the HIV inhibitors may be selected from one or more of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase preparations, protease inhibitors, or integrase inhibitors.
Nucleoside reverse transcriptase inhibitors include adefovir, azidothymidine, zalcitabine, lamivudine, emtricitabine, abacavir, fuzivudine tiate, alovudine, amdoxovir, elvucitabine, aliscitabine, and the like; non-nucleoside reverse transcriptase inhibitors include nevirapine, delavirdine, efavirenz, GSK2248761, lesivirin, etravirine, loviramine, oltipraz, carpivirine, and RDEA-806; protease inhibitors such as indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir, bacinavir, palinavir, lacinavir; integrase inhibitors include raltegravir, eltavir, Cabotegravir.
The treatment of HIV infection described in the present disclosure relates to the treatment of subjects infected with HIV, as well as to the treatment of diseases associated with HIV infection. The prevention of HIV infection relates to preventing or avoiding infection of a subject by HIV. The treatment of HIV infection described in the present disclosure refers to a treatment whereby the viral load of HIV is reduced. The long term treatment or long term prevention of HIV infection as described in the present disclosure refers primarily to treatment or prevention of HIV infection for at least one week, two weeks, four weeks, one month, or more.
Grinding apparatuses suitable for use in the present disclosure include dispersion mills such as ball mills, attritors, vibration mills, and the like, and media mills such as sand mills and bead mills. Such dispersion mills are well known in the art.
Detailed Description
In the description and claims of the present disclosure, unless otherwise indicated, scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. However, for a better understanding of the present disclosure, definitions and explanations of some of the relevant terms are provided below.
The solvent used in the co-milling in the present disclosure may be a liquid medium; the aqueous carrier in the injection solution may be a liquid medium, which is the same as that described above.
The saline solution described in the present disclosure includes, but is not limited to, physiological saline solution, buffered saline solution (including, but not limited to, ammonia-ammonium chloride buffer, citrate buffer, acetic acid-sodium acetate buffer, phosphate buffer).
The subject of the present disclosure is particularly a human.
As used herein, the "weight to volume ratio" (w/v) refers to the weight (in g) of the component per 100mL of liquid system, i.e., g/100 mL. When the substances in the pharmaceutical composition of the present disclosure are expressed by weight to volume ratio, the pharmaceutical composition further comprises a liquid medium, and the liquid medium is the same as the liquid medium described above.
As used herein, "D10" refers to the particle size corresponding to a cumulative percent particle size distribution of 10% for a sample. "D50" refers to the particle size corresponding to the cumulative percent particle size distribution of a sample at 50%. "D90" refers to the particle size corresponding to 90% of the cumulative percent particle size distribution for a sample.
The "average particle Size" (Z-average Size), e.g. "average particle Size less than 2000 nm", as used herein is the average of the intensities of light, as calculated from the intensities of light contributed by the different types of particles. The "average particle size" may be measured by conventional particle size measurement techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and the like.
The Polydispersity Index "PDI" (Polydispersity Index) of the present disclosure represents the degree of particle size uniformity, and is an important Index for particle size characterization.
The content (including percentage content) and the ratio of each substance in the composition are allowed to have a tolerance of +/-5%, for example, the fact that the content of rilpivirine in the composition is selected from 200-350 mg/mL means that the content of rilpivirine nanoparticles in the composition is 195-355 mg/mL, which belongs to the scope of the disclosure; "comprising 30% rilpivirine nanoparticles" means that it is within the scope of the disclosure to comprise 25-35% rilpivirine nanoparticles; the weight ratio of the sedimentation inhibitor to the rilpivirine nanoparticles is selected from 1: 3-1: 6, which means that the weight ratio of the sedimentation inhibitor to the rilpivirine nanoparticles is selected from 1: 2.5-1: 6.5 are within the scope of the present disclosure. In the present disclosure, "about" means a regimen that includes an error of ± 5%.
The terms "mixing" and "mixing" in the present disclosure mean not to limit the order of addition of the components, and for example, mixing a into B may mean adding a into B, or may mean adding B into a, or mixing a and B may mean adding a into B, or may mean adding B into a.
Advantageous effects of the invention
The present disclosure improves the dispersibility of nanoparticles in suspensions by adding a surface stabilizer to injectable pharmaceutical compositions comprising rilpivirine nanoparticles. The sedimentation or aggregation of the nanoparticles can be inhibited by adding a sedimentation inhibitor such as mannitol and anhydrous glucose into the composition. In some embodiments of the present disclosure, a nonionic surfactant, an anionic surfactant, a sedimentation inhibitor, etc. are selected to prepare rilpivirine nanoparticles together, the average particle size of the rilpivirine nanoparticles after grinding is less than 300nm, the average particle size does not increase significantly after storage for 30 days at 2-8 ℃, and the preparation is stable.
Detailed Description
The present disclosure is further illustrated in detail by the following examples and experimental examples. These examples and experimental examples are for illustrative purposes only and are not intended to limit the scope of the present disclosure.
The particle size of the nanoparticle injection in the following examples is measured by the third method of 0982, the fourth general rule of pharmacopoeia 2015 edition of china.
Malvern Nano-particle size potentiometer Zetasizer Nano ZS, dispersion medium: purifying the water; dilution times are as follows: diluting to rilpivirine concentration of about 0.06 mg/ml; and (3) testing temperature: 25 ℃; absorption rate: 0.01; a refractive index of 1.66; the balance time is as follows: 120 s; test position: the optimal position.
The average particle size described in the examples refers to the average particle size measured with a malvern Nano-particle size potentiometer Zetasizer Nano ZS.
Malvern laser sizer Mastersizer 2000, dispersion medium: purifying the water; sensitivity: normal; refractive index: 1.665; absorption rate: 0.01; background measurement time: 12 s; sample measurement time: 12 s; stirring speed: 1500 rpm; light-shielding degree range: 5 to 10 percent.
Polyethylene glycol 15-hydroxystearate (also known as polyethylene glycol-12-hydroxystearate, abbreviated as HS 15) with trade name(Basff, Germany).
EXAMPLE 1 preparation of Ripivirine starting Material
Rilpivirine free base was prepared according to CN100509801C specification example B1.
Example 2 prescription 1-rilpivirine, Poloxamer formulation
TABLE 1 formulation of rilpivirine and poloxamer
The preparation method comprises the following steps: dissolving a prescribed amount of poloxamer, anhydrous glucose, and about half of the total weight in water; adding the rilpivirine raw material with the prescription amount into the solution, adding water for injection to a target volume, and stirring and mixing uniformly by using a glass rod; the mixed solution was put into a grinding pot filled with grinding beads, stirred uniformly, and ground in a ball mill, and the grinding results are shown in table 2.
TABLE 2 grinding particle size results
The experimental results show that the average particle size can only be reduced to about 250 nm.
EXAMPLE 3 prescription of 2-rilpivirine, Tween 20 preparation
TABLE 3 formulation of rilpivirine and Tween 20
Specific procedures particle size was measured using malvern 2000 with reference to example 2, and the grinding results are shown in table 4 below.
TABLE 4 grinding particle size results
When the particle size is detected and sampled, the viscosity of the liquid medicine is higher, the sampling is difficult, the grinding is stopped, and the particle size distribution is wider.
Example 4 formulation of 3-rilpivirine, Povidone K17
TABLE 5 formulation of rilpivirine, povidone K17
The specific procedure is as in example 2, taking 0.1ml of the detected particle size, the grinding results are shown in Table 6 below.
TABLE 6 grinding particle size results
The particle size detection result shows that the particle size is larger and the distribution is wider.
Example 5 formulation of rilpivirine, polyethylene glycol 15-hydroxystearate
TABLE 7 formulation screening of rilpivirine and polyethylene glycol 15-hydroxystearate
The above proportions are weight to volume ratios.
The preparation method comprises the following steps: dissolving a prescribed amount of a stabilizer and a settling inhibitor in about half of the total weight of water; adding the rilpivirine raw material with the prescription amount into the solution, adding water for injection to a target volume, and stirring and mixing uniformly by using a glass rod; adding the mixed solution into a grinding tank filled with grinding beads, stirring, taking 0.1ml to detect the particle size, and the grinding results are shown in Table 8 below
TABLE 8 grinding particle size results
From the data in table 8, it can be seen that the formulation of formula 4 does not allow the particle size to be reduced below 300 nm; formula 5 has low grinding efficiency, small particle size reduction range and wide particle size distribution; the average particle diameter of the rest formulas can be less than 250 nm.
TABLE 9 formulation of rilpivirine, polyethylene glycol 15-hydroxystearate, glucose
The above proportions are weight to volume ratios.
The preparation method comprises the following steps: dissolving a prescribed amount of a stabilizer and a settling inhibitor in about half of the total weight of water; adding the rilpivirine raw material with the prescription amount into the solution, adding water for injection to a target volume, and stirring and mixing uniformly by using a glass rod; the mixed solution was put into a grinding pot filled with grinding beads and stirred uniformly, and 0.1ml of the mixed solution was taken out to measure the particle size, and the grinding results are shown in the following table 10.
TABLE 10 results of grinding particle size
As can be seen from the data in Table 10, the average particle size was less than 300nm and the PDI was below 0.5 for all formulations 9-15 after milling, the particle size and distribution results for the drug were good.
Example 6 stability Studies of Ripivirine formulation formulations
The nanosuspensions obtained by the formulas 7-10 and 15 were placed at 2-8 ℃ under the condition of humidity replenishment, and the particle size distribution was examined for about 0-30 days, as shown in table 11.
TABLE 11 particle size stability data for recipe 6, recipe 7, recipe 8, recipe 9, and recipe 10
As can be seen from the data in table 11, the rilpivirine nanoparticle injection is stable under the above conditions, and the particle size distribution is not significantly changed from the initial one.
Claims (23)
1. A pharmaceutical composition comprising rilpivirine nanoparticles and a surface stabilizer, wherein the surface stabilizer comprises a first surface stabilizer polyethylene glycol stearate or a derivative thereof and a second surface stabilizer selected from one or more of sodium deoxycholate, sodium cholate, sodium hydroxymethylcellulose, sodium docusate, preferably one or more of sodium deoxycholate, sodium hydroxymethylcellulose, more preferably sodium deoxycholate.
2. The pharmaceutical composition according to claim 1, wherein the polyethylene glycol stearate or derivative thereof is selected from 15-hydroxypolyethylene glycol stearate, and the second surface stabilizer is selected from sodium deoxycholate, sodium cholate, sodium hydroxymethylcellulose, sodium docusate, preferably one or more of sodium deoxycholate and sodium hydroxymethylcellulose, more preferably sodium deoxycholate.
3. The pharmaceutical composition according to claim 2, wherein the weight ratio of the first surface stabilizer to rilpivirine is selected from 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 6-1: 60, most preferably 1: 10-1: 30.
4. The pharmaceutical composition according to claim 2, wherein the weight ratio of the secondary surface stabilizer to rilpivirine is selected from 1: 0.01-1: 100, preferably 1: 1-1: 100, more preferably 1: 10-1: 60, most preferably 1: 20-1: 60.
5. The pharmaceutical composition according to any one of claims 1-4, wherein the weight ratio of the first surface stabilizer to the second surface stabilizer is selected from 0.1:1 to 10:1, preferably 1:1 to 6:1, more preferably 1:1 to 2:1, most preferably 2: 1.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the weight ratio of surface stabilizer to rilpivirine is selected from 1:0.01 to 1:100, preferably 1:1 to 1:80, more preferably 1:5 to 1:30, most preferably 1:6.5 to 1: 20.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the weight ratio of sodium deoxycholate, 15-hydroxystearic acid polyethylene glycol ester and rilpivirine is 1: 1-10: 1-100, preferably 1: 1-6: 10-100, more preferably 1: 1-5: 10-80, and most preferably 1: 1-3: 20-60.
8. The pharmaceutical composition according to any one of claims 1-7, wherein said pharmaceutical composition further comprises a sedimentation inhibitor.
9. The pharmaceutical composition according to claim 8, wherein the sedimentation inhibitor is selected from one or more of mannitol, glucose, sucrose, polyethylene glycol, dextran 40, trehalose, glycerol, povidone, glycine, hydroxypropyl- β -cyclodextrin, preferably one or more of mannitol, glucose, polyethylene glycol, more preferably glucose.
10. The pharmaceutical composition of claim 9, wherein the weight ratio of the sedimentation inhibitor to rilpivirine is selected from 1:0.1 to 1:50, preferably 1:0.5 to 1:30, more preferably 1:3 to 1:15, most preferably 1:3 to 1: 7.
11. The pharmaceutical composition according to any one of claims 1-10, wherein the pharmaceutical composition comprises rilpivirine in an amount selected from the group consisting of 0.01-800mg, preferably 10-600mg, more preferably 100-600mg, most preferably 200-600 mg.
12. The pharmaceutical composition according to claims 1-11, wherein the pharmaceutical composition further comprises a liquid medium selected from one or more of water, saline solution, preferably water.
13. The pharmaceutical composition according to claim 12, wherein the content of rilpivirine in the pharmaceutical composition is selected from 0.01-800 mg/mL, preferably 10-600 mg/mL, more preferably 100-500 mg/mL, most preferably 200-350 mg/mL.
14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the rilpivirine nanoparticles have an average particle size of less than 500nm, preferably less than 250nm, more preferably less than 200nm, most preferably less than 150 nm.
15. The pharmaceutical composition of claim 14, wherein the average particle size of rilpivirine nanoparticles is no greater than 500nm, preferably no greater than 300nm, more preferably no greater than 250nm, most preferably no greater than 200nm, when the pharmaceutical composition is stored at 2-8 ℃ for about 30 days.
16. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition has a D50 value for rilpivirine nanoparticles of no greater than 500nm, preferably no greater than 300nm, more preferably no greater than 250nm, most preferably no greater than 200nm, when stored at 2-8 ℃ for about 30 days.
17. The pharmaceutical composition of claim 14, wherein the D90 of rilpivirine nanoparticles is no greater than 600nm, preferably no greater than 500nm, more preferably no greater than 350nm, most preferably no greater than 300nm, when the pharmaceutical composition is stored at 2-8 ℃ for about 30 days.
18. The pharmaceutical composition of any one of claims 1-17, wherein the pharmaceutical composition is prepared as an injection solution or a lyophilized formulation.
19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition comprises, based on the weight to volume ratio of the composition:
a) 3-50% w/v rilpivirine, preferably 10-40% w/v rilpivirine, more preferably 20-40% w/v rilpivirine;
b) 0.1-10% w/v of polyethylene glycol 15-hydroxystearate, preferably 0.5-5% w/v of polyethylene glycol 15-hydroxystearate, more preferably 0.5-3% w/v of polyethylene glycol 15-hydroxystearate;
c) 0.01-3% w/v sodium deoxycholate, preferably 0.1-1.5% w/v sodium deoxycholate, more preferably 0.5-1.5% w/v sodium deoxycholate;
d) 0% to 10% w/v glucose, preferably 3% to 8% w/v glucose, more preferably 4% to 6% w/v glucose;
e) from 40% to 80% w/v water, preferably from 50% to 80% w/v water, more preferably from 60% to 75% w/v water.
20. A process for preparing a pharmaceutical composition according to any one of claims 1 to 19, comprising: co-milling the surface stabilizer with rilpivirine to prepare the nanoparticle composition.
21. A method of preparing the pharmaceutical composition of claim 20, comprising: co-milling the surface stabilizer, the sedimentation inhibitor and rilpivirine to prepare the nanoparticle composition.
22. Use of a pharmaceutical composition according to any one of claims 1-19 for the manufacture of a medicament for treating HIV infection or preventing HIV infection in a subject at risk of being infected by HIV.
23. The use according to claim 22, wherein the pharmaceutical composition is used in combination with other HIV inhibitors, wherein the HIV inhibitors may be selected from one or more of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase preparations, protease inhibitors or integrase inhibitors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010220470 | 2020-03-25 | ||
CN2020102204704 | 2020-03-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113440529A true CN113440529A (en) | 2021-09-28 |
CN113440529B CN113440529B (en) | 2023-11-14 |
Family
ID=77809366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110317250.8A Active CN113440529B (en) | 2020-03-25 | 2021-03-25 | Injectable pharmaceutical composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113440529B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070178165A1 (en) * | 2005-12-15 | 2007-08-02 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for parenteral administration |
CN101478950A (en) * | 2006-06-23 | 2009-07-08 | 泰博特克药品有限公司 | Aqueous suspensions of TMC278 |
CN101636149A (en) * | 2007-03-14 | 2010-01-27 | 泰博特克药品有限公司 | The powder that is used to reconstitute |
CN103764117A (en) * | 2011-04-15 | 2014-04-30 | 詹森药业有限公司 | Freeze dried drug nanosuspensions |
US20140212501A1 (en) * | 2011-09-09 | 2014-07-31 | The University Of Liverpool | Compositions of lopinavir |
US20140220140A1 (en) * | 2011-09-09 | 2014-08-07 | The University Of Liverpool | Compositions of efavirenz |
WO2015136294A1 (en) * | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
WO2019037757A1 (en) * | 2017-08-24 | 2019-02-28 | 江苏恒瑞医药股份有限公司 | Injectable pharmaceutical composition containing meloxicam, and preparation method therefor |
WO2020034989A1 (en) * | 2018-08-14 | 2020-02-20 | 江苏恒瑞医药股份有限公司 | Injectable pharmaceutical composition and preparation method therefor |
-
2021
- 2021-03-25 CN CN202110317250.8A patent/CN113440529B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070178165A1 (en) * | 2005-12-15 | 2007-08-02 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for parenteral administration |
CN101478950A (en) * | 2006-06-23 | 2009-07-08 | 泰博特克药品有限公司 | Aqueous suspensions of TMC278 |
CN101636149A (en) * | 2007-03-14 | 2010-01-27 | 泰博特克药品有限公司 | The powder that is used to reconstitute |
CN103764117A (en) * | 2011-04-15 | 2014-04-30 | 詹森药业有限公司 | Freeze dried drug nanosuspensions |
US20140212501A1 (en) * | 2011-09-09 | 2014-07-31 | The University Of Liverpool | Compositions of lopinavir |
US20140220140A1 (en) * | 2011-09-09 | 2014-08-07 | The University Of Liverpool | Compositions of efavirenz |
WO2015136294A1 (en) * | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
WO2019037757A1 (en) * | 2017-08-24 | 2019-02-28 | 江苏恒瑞医药股份有限公司 | Injectable pharmaceutical composition containing meloxicam, and preparation method therefor |
WO2020034989A1 (en) * | 2018-08-14 | 2020-02-20 | 江苏恒瑞医药股份有限公司 | Injectable pharmaceutical composition and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
CN113440529B (en) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohammad et al. | Drug nanocrystals: Fabrication methods and promising therapeutic applications | |
JP4831965B2 (en) | Nanoparticle formulations comprising HMG-CoA reductase inhibitor derivatives ("statins"), novel combinations thereof, and the manufacture of these pharmaceutical compositions | |
US20070077286A1 (en) | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | |
MX2007015309A (en) | Nanoparticulate imatinib mesylate formulations. | |
SG175314A1 (en) | A novel formulation of diclofenac | |
JP2008531591A (en) | Nanoparticulate formulations of docetaxel and their analogs | |
IL247034A (en) | Formulation of indomethacin | |
CN101797245A (en) | Nanoparticulate fibrate formulations | |
JP2005531605A (en) | Nanoparticulate policosanol formulations and novel policosanol combinations | |
CN101636150A (en) | Method for producing pulverized organic compound particle | |
EP1414410B1 (en) | Nanoparticulate formulations of fenofibrate | |
KR20210044245A (en) | Injectable pharmaceutical composition and method for preparing same | |
CN104602675B (en) | The method of the nanoparticle of indigo red, its derivative and the manufacture and use nanoparticle | |
JP2013509361A (en) | Taxol submicroemulsion with steroid compound as intermediate carrier | |
KR20170056702A (en) | Long acting pharmaceutical compositions | |
US20230067593A1 (en) | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3 -yl]pyrimidin-5-yl} carbamate | |
US20130210794A1 (en) | Nanostructured ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
CN113440529B (en) | Injectable pharmaceutical composition and preparation method thereof | |
US10603277B2 (en) | Nanoparticulate formulation comprising a TRPA1 antagonist | |
KR20170110285A (en) | Erlotinib nanoparticles and a method for preparing the same, and a pharmaceutical composition containing Erlotinib nanoparticles | |
WO2022175903A1 (en) | Preparation of soluble form of curcumin | |
CN113384527A (en) | A pharmaceutical composition containing papaverine or its salt and its preparation method | |
CN113521292A (en) | Compound preparation of COX-2 inhibitor and tramadol | |
CN116528840A (en) | Intracellular ATP enhancer | |
CA3178610A1 (en) | Nanoparticulate composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |